This script search US Code. View Rule
Skip past Nav Bar
GSA - U.S. General Services Administration Office of Management and Budget
RegInfo.gov Where to find Federal Regulation Information US Flag
Home
Background Image Spacer Unified Agenda and Regulatory Plan Spacer EO 12866 Regulatory Review Spacer Information Collection Review
Current Unified Agenda and Regulatory Plan Historical Unified Agenda and Regulatory Plan Search

View Rule

Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AA97 Publication ID: Spring 2008 
Title: Safety Reporting Requirements for Human Drug and Biological Products 
Abstract: These regulations are one component of the Secretary's initiative to reduce medical errors. The final rule would amend the expedited and periodic safety reporting regulations for human drugs and biological products to revise certain definitions and reporting formats as recommended by the International Conference on Harmonisation and to define new terms; to add to or revise current reporting requirements; to revise certain reporting time frames; and to propose other revisions to these regulations to enhance the quality of safety reports received by FDA. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Undetermined  Unfunded Mandates: Undetermined 
CFR Citation: 21 CFR 310; 21 CFR 312; 21 CFR 314; 21 CFR 320; 21 CFR 600; 21 CFR 601; 21 CFR 606 (To search for a specific CFR, visit the Code of Federal Regulations.
Legal Authority: 42 USC 216; 42 USC 241; 42 USC 242a; 42 USC 262; 42 USC 263; 42 USC 263a to 263-n; 42 USC 264; 42 USC 300aa; 21 USC 321; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 360b to 360j; 21 USC 361a; 21 USC 371; 21 USC 374; 21 USC 375; 21 USC 379e; 21 USC 381 
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  03/14/2003  68 FR 12406 
NPRM Comment Period Extended  06/18/2003   
NPRM Comment Period End  07/14/2003   
NPRM Comment Period Extension End  10/14/2003   
Final Action  04/00/2009   
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: Undetermined 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: Yes 
Agency Contact:
Carol Drew
Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Suite 3037 (HFD-7), Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Bldg. 51, Room 6306,
Silver Spring, MD 20993-0002
Phone:301 796-3601
Fax:301 847-8440

 
Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us